FMC Corporation Acquires BioPhero ApS

BioPhorum Acquires PharmaX Solutions

May 7, 2026

IT Services

BioPhorum has acquired PharmaX Solutions, a consultancy specializing in digital transformation and end-to-end digital manufacturing solutions for pharmaceutical manufacturing environments. The acquisition expands BioPhorum’s Implementation Services offering and extends its international footprint across offices in Germany, Spain, Denmark, and Switzerland.

Merck Acquires Prometheus Biosciences

June 16, 2023

Healthcare Services

Merck (MSD outside the United States and Canada) entered into a definitive agreement to acquire Prometheus Biosciences for $200 per share in cash, valuing the equity at approximately $10.8 billion. The acquisition was expected to close in the third quarter of 2023, and Merck later announced completion of the deal, making Prometheus a wholly owned subsidiary.

Valent BioSciences Acquires FBSciences

January 30, 2023

Agriculture

Valent BioSciences LLC, a subsidiary of Sumitomo Chemical Co., Ltd., has acquired FBSciences Holdings, Inc., a Collierville, Tennessee–headquartered developer of naturally derived biostimulants, biopesticides, and crop nutrition solutions. The acquisition strengthens Valent's capabilities and market position in the rapidly growing global biostimulant and biorationals market.

Pharmacosmos A/S Acquires AbFero Pharmaceuticals, Inc.

November 11, 2021

Pharmaceuticals

Pharmacosmos A/S (Pharmacosmos Group) has agreed to acquire all assets of Boston-based clinical-stage AbFero Pharmaceuticals, Inc. under a share purchase agreement for up to $225 million including upfront, milestone, and royalty components. The acquisition adds AbFero’s SP-420 iron chelation program to Pharmacosmos’ iron-metabolism-focused R&D and commercial capabilities to accelerate development and commercialization for transfusional iron overload and related indications.

Servier Acquires Symphogen A/S from Novo Holdings and Other Owners

April 3, 2020

Biotechnology

Servier has acquired 100% of the share capital of Symphogen A/S from Novo Holdings and the remaining owners, taking ownership of the Danish therapeutic antibody discovery and early biologics development company. The deal brings Symphogen’s antibody discovery platform and CMC biologics development capabilities into Servier’s oncology and immuno-oncology R&D efforts to strengthen its biologics pipeline and development capacity.

Novozymes A/S Agrees to Acquire GroPep Limited

August 15, 2006

Biotechnology

Novozymes A/S has proposed to acquire all issued securities of Australian biotech GroPep Limited via a scheme of arrangement, offering A$2.05 per share and valuing GroPep at approximately A$96 million. The transaction is subject to typical scheme and regulatory approvals, with completion expected by end of 2006, and is intended to expand Novozymes' biopharmaceutical/recombinant-ingredient capabilities and market access.